This tyrosine kinase inhibitor (TKI) impairs the interaction of BCR-ABL1 and ATP, blocking cell signals and, consequently, reducing cell proliferation and inducing cell death f CML clones. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.